Recombinant hirudin (HBW 023): Biologica
โ
F. Bridey; M. Dreyfus; F. Parent; A. Bros; A. M. Fischer; A. Camez; G. Simonneau
๐
Article
๐
1995
๐
John Wiley and Sons
๐
English
โ 530 KB
This study reports on the biological data of ten patients with acute venous thrombo-embolism. They were treated for 5 days with continuous intravenous infusion of a fixed dose (0.05 mg/kg/hr) of a recombinant hirudin (r-H HBW 023 Behringwerke, Germany). The plasma level of r-H (HBW 023), assessed by